Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals
NCT00001760 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2007-12-13
Summary
Cytokine Production Patterns in Patients with Systemic Mastocytosis Compared with Atopic Dermatitis and Healthy Individuals
Summary: This study will examine how mast cells (cells involved in allergic reactions) migrate and multiply in the skin of patients with mastocytosis, a condition characterized by too many mast cells in the body. The mast cells tend to multiply in the skin, causing dark, itchy skin spots known as urticaria pigmentosa. This study will determine if the skin of patients with mastocytosis produces chemicals called cytokines that cause mast cells to migrate to the skin and multiply. The findings will be compared with those from normal volunteers and patients with atopic dermatitis, a skin disease characterized by recurrent itchy rash usually seen in people with a family history of allergies.
Healthy volunteers, patients with mastocytosis and patients with atopic dermatitis 18 years of age and older may be eligible for this study. Participants will have the following tests and procedures:
* Suction blisters - Two to eight small blisters will be raised on the forearm using gentle suction. The fluid in the blisters will be collected with a syringe to study the chemicals produced by the skin. The tops of the blisters may be removed for research.
* Template study - Patients with high cytokine content in the blister fluid may have a template study. For this procedure, a plastic block (template) with holes matching the blister sites is placed over the blistered area. The wells of the template are filled with salt water and the fluid is removed with a syringe at 3, 8 and/or 24 hours. Patients are hospitalized for 24 hours for this study.
* Skin biopsy - A skin biopsy will be done to correlate cytokine levels with the number of mast cells in the skin. An area of skin is numbed with an anesthetic and a small circular area about the size of a pencil eraser is removed, using a sharp cookie cutter-type instrument.
* Blood draw - About 4 tablespoons of blood will be drawn to compare the chemicals in the blood with those in the blister fluid. The blood will also be analyzed for a complete blood count, clotting factors and substances that may be elevated in people with allergies.
Conditions
- Atopic Dermatitis
- Healthy
- Mastocytosis
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 1998-01-31
- Completion
- 2001-12-31
Countries
- United States
Study Locations
More Related Trials
-
A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)
NCT01732510 ·Status: TERMINATED ·Phase: PHASE1
-
Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis
NCT06553209 ·Status: COMPLETED ·Phase: PHASE1
-
The Role of IL-22/IL-22BP Axis in Atopic Dermatitis
NCT04310189 ·Status: COMPLETED ·Phase: NA
-
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
NCT05186922 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
NCT01675232 ·Status: COMPLETED ·Phase: NA
-
Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults
NCT07276620 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT06397911 ·Status: RECRUITING ·Phase: PHASE2
-
Sublingual Immunotherapy in Patients With Atopic Dermatitis
NCT01471119 ·Status: COMPLETED ·Phase: PHASE2
-
Bone Health in Patients With Atopic Dermatitis
NCT03800004 ·Status: COMPLETED
-
A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis
NCT01614756 ·Status: COMPLETED ·Phase: PHASE1
-
Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up
NCT00795496 ·Status: COMPLETED
-
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
NCT00125333 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis
NCT06922565 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
NCT04444752 ·Status: COMPLETED ·Phase: PHASE2
-
Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis
NCT01678092 ·Status: COMPLETED ·Phase: PHASE1
-
Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis
NCT06026891 ·Status: RECRUITING ·Phase: PHASE3
-
Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
NCT06947980 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
NCT07103174 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis
NCT06277765 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis
NCT04413942 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
NCT04504279 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
NCT05702268 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
NCT02975206 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
NCT02317276 ·Status: TERMINATED ·Phase: PHASE4